EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study

Andrew W Ngai, Aqsa Baig, Muhammad Zia iD, Karen Arca-Contreras, Nadeem Ul Haque, Veronica Livetsky, Marcelina Rokicki, Shiryn D Sukhram iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157412 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Andrew W Ngai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: City University of New York, PSC-CUNY Award, Professional Staff Congress.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic nephropathy affects approximately 30–40% of individuals with diabetes mellitus (DM) and is a major contributor to end-stage renal disease (ESRD). While angiotensin II receptor blockers (ARBs) have long served as a standard treatment, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently gained attention for their renal and cardiovascular benefits. However, comparative real-world data on their long-term renal effectiveness remain limited. We conducted a retrospective, longitudinal study over a 2-year period to compare the impact of ARB monotherapy versus SGLT2i and angiotensin-converting enzyme inhibitor (ACEi) combination therapy on the progression of chronic kidney disease (CKD) in patients with DM. A total of 126 patients were included and grouped based on treatment regimen. Renal biomarkers were analyzed using t-tests and ANOVA (p < 0.01). Albuminuria was qualitatively classified via urinalysis as negative, level 1 (+1), level 2 (+2), or level 3 (+3). The ARB group demonstrated higher estimated glomerular filtration rate (eGFR) and lower serum creatinine (sCr) levels than the combination therapy group, with glycated hemoglobin (HbA1c), potassium (K+), and blood pressure remaining within normal limits in both cohorts. Albuminuria remained stable over time, with 60.8% of ARB users and 73.1% of combination therapy users exhibiting persistently or on-average negative results. Despite the expected additive benefits of SGLT2i/ACEi therapy, ARB monotherapy was associated with slightly more favorable renal function markers and a lower incidence of severe albuminuria. These findings suggest a need for further controlled studies to clarify the comparative long-term renal effects of these treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAngiotensin-Converting Enzyme InhibitorsDiabetic NephropathiesAngiotensin Receptor AntagonistsDiabetes Mellitus, Type 2HumansMaleFemaleRetrospective StudiesMiddle AgedLongitudinal StudiesAgedDrug Therapy, CombinationGlomerular Filtration RateKidneyRenal Insufficiency, ChronicGlycated HemoglobinBiomarkersCreatinineAlbuminuria

Stichwörter der Autor:innen

angiotensin II receptor blockersangiotensin-converting enzyme inhibitorschronic kidney diseasediabetic kidney diseasediabetic nephropathysodium-glucose cotransporter-2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsGlycated HemoglobinBiomarkersCreatinine

Autor:innen und Institutionen

  • Department of Biology, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 6S, Staten Island, NY 10314, USA.
  • Department of Environmental and Public Health Sciences, University of Cincinnati, 160 Panzeca Way, Kettering Lab Building, Cincinnati, OH 45267, USA.
  • Nursing Department, College of Staten Island, City University of New York, 2800 Victory Boulevard, Building 5S, Staten Island, NY 10314, USA.
  • AZZ Medical Associates, 631 Broadway, Suite 2, Bayonne, NJ 07002, USA.

ORCID-Profile: Muhammad Zia, Shiryn D Sukhram

Förderung

  • City University of New York
  • PSC-CUNY Award
  • Professional Staff Congress

Zitieren

APA

Ngai, A. W., Baig, A., Zia, M., Arca-Contreras, K., Haque, N. U., Livetsky, V., Rokicki, M., & Sukhram, S. D. (2025). Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157412

Vancouver

Ngai AW, Baig A, Zia M, Arca-Contreras K, Haque NU, Livetsky V, et al. Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157412

BibTeX
@article{Ngai2025,
  author = {Ngai, Andrew W and Baig, Aqsa and Zia, Muhammad and Arca-Contreras, Karen and Haque, Nadeem Ul and Livetsky, Veronica and Rokicki, Marcelina and Sukhram, Shiryn D},
  title = {Comparative Evaluation of ARB Monotherapy and SGLT2/ACE Inhibitor Combination Therapy in the Renal Function of Diabetes Mellitus Patients: A Retrospective, Longitudinal Cohort Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157412}
}
Kostenlos starten →